--- title: 'Clinical Daily Summary: What Happened on November 8, 2026' headline: Semaglutide lowers heart-filling pressures in a small HFpEF trial description: A cardiac imaging substudy found changes in heart function measures that may help explain the pressure reductions. url: https://thebench.bio/news/clinical/2026-11-08 topic: clinical date: '2026-11-08' covers: - '2026-11-08' date_published: '2026-11-08T12:00:28Z' date_modified: '2026-11-09T00:00:37Z' tags: - Clinical sources: 2 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on November 8, 2026 **Semaglutide lowers heart-filling pressures in a small HFpEF trial** A cardiac imaging substudy found changes in heart function measures that may help explain the pressure reductions. ## Today in brief In 81 people with obesity and heart failure with preserved ejection fraction, semaglutide reduced pressure in the heart during exercise over 52 weeks. [1] Scans of 49 participants also showed changes in heart structure and function. [2] ## Semaglutide reduced heart-filling pressures in obesity-related HFpEF Researchers randomly assigned 81 participants to weekly semaglutide or placebo in a double-blind trial lasting 52 weeks. [1] During exercise, pulmonary artery wedge pressure, a measure of pressure inside the heart, fell by 9.8 mmHg with semaglutide and rose by 0.9 mmHg with placebo. [1] The estimated difference between groups was −10.6 mmHg. [1] At rest, the estimated reduction with semaglutide was 7.1 mmHg greater than with placebo. [1] Hemodynamic remission, defined by specified pressure thresholds, occurred in 53.7% of the semaglutide group and 7.4% of the placebo group. [1] Novo Nordisk supplied the semaglutide and matching placebo. [1] ## Imaging substudy connects heart-function changes with pressure reductions In a prespecified magnetic resonance substudy, 49 participants had scans at the start of the trial and after 52 weeks. [2] Compared with placebo, semaglutide improved left atrial reservoir strain by 5.7% and the indexed early filling rate of the left ventricle by 0.64 s−1. [2] Both measures were associated with lower exercise pulmonary artery wedge pressure. [2] The substudy also found lower left ventricular mass, more physiologic ventricular geometry, and improved right ventricular function and mechanics in both ventricles. [2] The authors said these changes may help explain semaglutide’s hemodynamic effects in people with obesity-related HFpEF. [2] ## The day in numbers - **81 participants**: People with obesity and HFpEF enrolled in the randomized semaglutide trial. [1] - **−10.6 mmHg**: Estimated difference between semaglutide and placebo in change in exercise heart-filling pressure at 52 weeks. [1] - **53.7% vs. 7.4%**: Share of participants with hemodynamic remission on semaglutide versus placebo. [1] - **49 participants**: People included in the magnetic resonance substudy. [2] ## Also published - [When genetic medicine enters the inner ear](), European Biotechnology - [STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype](), STAT Biotech ## Sources 1. [Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial](), Nature Medicine, 2026-11-08 2. [Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial](), Nature Medicine, 2026-11-08 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: